| |
Tuesday, August 27, 2024 | 12pm ET / 9am PT Join us for a one-hour, comprehensive discussion on the importance of leveraging federated AI for innovative data collection in real-world research. Register now.
|
|
Today’s Big NewsAug 13, 2024 |
| By Nick Paul Taylor Rivus Pharmaceuticals has plumped up the prospects of its fat busting, muscle sparing drug candidate, reporting a primary endpoint hit in a phase 2a trial of people with obesity-related heart failure. |
|
|
|
By Gabrielle Masson The journal Psychopharmacology has pulled three articles about several midstage clinical trials assessing Lykos Therapeutics’ investigational MDMA candidate for treating post-traumatic stress disorder. The journal cited “unethical conduct” at a research site as the reason for the retraction. |
By James Waldron Only five months after securing a $100 million IPO, Boundless Bio is already laying off some employees as the precision oncology company grapples with low enrollment for a trial of its lead drug. |
By Nick Paul Taylor Eli Lilly has opened a $700 million R&D center in the Boston Seaport, boosting its RNA and DNA research capabilities and expanding its biotech-hosting Gateway Labs to the East Coast for the first time. |
By James Waldron “Following Takeda's unexpected phase 3 results for soticlestat, we moved rapidly to focus our resources to preserve capital,” Ovid CEO Jeremy Levin said. |
By Gabrielle Masson,Darren Incorvaia,Max Bayer We really didn't want to have to create another Layoff Tracker this year. But here we are, launching the third annual iteration tracking biopharma layoffs. |
By Heather Landi 23andMe plans to launch a GLP-1 weight loss telehealth membership through its Lemonaid Health platform by the end of the month. |
By Fraiser Kansteiner Despite hitting a roadblock on the path to approval for its once-weekly insulin icodec in the United States, Novo Nordisk is continuing to move full speed ahead with a combo treatment pairing the drug with its unstoppable GLP-1 semaglutide. |
By Paige Minemyer Prior authorization denials in Medicare Advantage jumped between 2021 and 2022, according to a new analysis from KFF. |
Fierce podcastsDon’t miss an episode |
| | This week on “The Top Line,” we dive into two studies in HIV research that were presented at the 25th International AIDS Conference in Germany. |
|
|---|
|
|
| WhitepaperThis paper explores the costs of setting up a supply chain in Europe for a new biopharma therapy. It outlines key cost drivers & the various levers decision makers can use to affect those costs. Sponsored by: AIM |
| WhitepaperDownload the white paper to learn how this innovative solution can help optimize your mAb production processes. The findings demonstrate the system's robust capability to sustain strong cell growth and high productivity, facilitating a smooth transition from laboratory to production scale. Sponsored by: Thermo Fisher Scientific |
| WhitepaperThe definitive report on the state of our industry. Readers will gain an understanding of key indicators to monitor, future predictions, and guidance for investors and founders navigating the therapeutic enabling tools and services, healthtech and techbio sectors through 2024 and beyond. Sponsored by: AVANT BIO |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
